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Abstract: This study was an attempt to establish the extent of increased oxida-
tive stress in hypercholesterolemic patients and to evaluate the effect of ator-
vastatin on the oxidative stress and antioxidant status. Blood samples of 15 
subjects (age and sex matched) from three groups: group I (healthy subjects), 
group II (hypercholesterolemic patients with atorvastatin treatment) and group 
III (hypercholesterolemic patients without any hypolipidemic drug) were taken 
and centrifuged to separate the plasma, which was used for the determination 
of vitamin E. The separated cells were washed thrice with 0.90 % w/v cold nor-
mal saline and used for the assay of the percentage hemolysis of the RBCs, and 
the determination of malondialdehyde, superoxide dismutase and hemoglobin. 
The levels of oxidative stress were higher in the hypercholesterolemic in com-
parison to the control and atorvastatin group. The levels of antioxidants were 
higher in the atorvastatin group than in the hypercholesterolemic one but were 
lower than the controls. From these findings, it was concluded that there is an 
increase in oxidative stress in hypercholesterolemia but it decreased signifi-
cantly after 2 months of atorvastatin therapy and antioxidant status also im-
proves in patients taking atorvastatin. 
Keywords: atorvastatin; oxidative stress; antioxidant effects; hypercholesterole-
mic patients. 
INTRODUCTION 
Statins, such as atorvastatin, significantly reduce cholesterol synthesis through 
inhibition of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase and are 
widely prescribed for hyperlipidemia to reduce the risk of atherosclerotic com-
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plications.1 Their efficacy in reducing cardiovascular morbidity and mortality 
was demonstrated in large intervention trials.1 However, debate continues as to 
whether the beneficial effects of statins can be ascribed purely to their ability to 
reduce cholesterol or whether additional actions, independent of lowering cho-
lesterol, play a significant role.1–3 Studies showed that oxidized low density lipo-
protein (LDL) is a major correlate of oxidative stress in hypercholesterolemic pa-
tients and that statins may reduce oxidative stress by reducing enhanced plasma 
levels of LDL, which are more susceptible to peroxidation in hypercholestero-
lemia, and change the LDL structure, making them more resistant to peroxida-
tion.1,4,5 Some studies further showed that statins may also inhibit NAD(P)H 
oxidase, thus decreasing the generation of reactive oxygen species (ROS), there-
by adding or synergizing the biological effects of antioxidants.4,6 Some studies 
also showed that statins or their metabolites may act as antioxidants, directly or 
indirectly by removing “aged LDL”, which is more prone to oxidation, from the 
circulation.7 Based on these findings, it is evident that among their properties, 
statins also possess antioxidant activities.8,9 Therefore, the aim of the present in-
vestigation was to evaluate the scientific evidence of atorvastatin having such an 
effect and its possible clinical relevance. The antioxidant effects of statins con-
tribute to the inhibition of atherogenesis, stabilization of atherosclerotic plaque, 
inhibition of myocardial hypertrophy and remodeling and modulation of vascular 
tone.6 Based on these arguments, which formed the backbone of this study, an 
attempt was made to determine whether there really is increased oxidative stress 
in hypercholesterolemics and if it is relatively decreased following atorvastatin 
therapy when compared to normal individuals. 
In this study, the levels of malondialdehyde (MDA), percentage hemolysis 
and superoxide dismutase (SOD) in red blood cells and vitamin E in plasma were 
measured. Red blood cells were chosen as they are well known to be subject to 
increased hazards of free radical damage. Moreover, these cells have a finite life 
span in circulation and their sequestration and disposal by macrophages may be 
related to the extent of peroxidative damage of their membrane lipids, cytoske-
letal proteins and enzymes. 
EXPERIMENTAL 
Study population 
This study was conducted on 3 groups each of 15 subjects in the age group 40–70 years. 
Both male and female subjects were taken in all groups. 
Group I consisted of 15 healthy subjects (8 males and 7 females) in the age range 40–70 
years having a normal lipid profile (control group). 
Group II consisted of 15 patients (8 males and 7 females) who had already been diagno-
sed as hypercholesterolemic and who had been treated with HMG–CoA reductase inhibitors 
(atorvastatin) for a minimum of 2 months at a minimum dosage of 10 mg/day of atorvastatin. 
Treatment with atorvastatin was given only in this group in order to compare the results with 
control and hypercholesterolemic group without administration of any hypolipidemic drug. 
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Group III consisted of 15 (8 males and 7 females) recently diagnosed hypercholestero-
lemic patients who were not taking any lipid lowering agent (hypercholesterolemic group). 
Selection of cases 
The test groups II and III for this study, consisting of 15 individuals in each group, were 
taken from the following hospitals: 1) the K. M. C. Hospital, Ambedkar Circle; 2) the K. M. 
C. Hospital, Attavar; 3) the Yenepoya Hospital, Kodialbail; 4) the A. J. Institute of Medical 
Sciences, Kuntikana; 5) the City Hospital, Kadri; 6) the Ullal General Hospital, Kudroli and 
7) the Dr. Uday Nayak Clinic, Bejai, all in Mangalore, India. 
While choosing the subjects for the test and control groups, care was taken to eliminate 
those with habits such as smoking, tobacco chewing, and alcohol consumption, as well as 
those with a history of chronic inflammatory disease such as tuberculosis, rheumatoid arthri-
tis, diabetes mellitus and malignancy, all of which play a vital role in contributing to oxidative 
stress injury. Approval to perform these studies on human subjects was obtained from the 
Institutional Clinical Ethics Committee of the Kasturba Medical College, Mangalore, India, 
and their guidelines were followed throughout the studies. 
Sample collection 
Venous blood (5.0 ml) was collected in ethylenediaminetetraacetic acid (EDTA) con-
tainers from the median cubital vein or basilic vein of each study subject under strictly aseptic 
conditions. The blood samples were centrifuged at 3000 rpm for 10 min within 3 h of collec-
tion. The plasma was separated and used for the determination of vitamin E. The separated 
cells were washed thrice with 0.90 % w/v cold normal saline, after which they were suspen-
ded in an equal volume of the same saline solution. This was then stored as a 50 % cell sus-
pension in a refrigerator (4–5 °C) until used for the assay of: 
– percentage hemolysis of RBCs at 0 and 2 h (which represented before and after incu-
bation with hydrogen peroxide, respectively); 
– malondialdehyde (MDA); 
– superoxide dismutase (SOD); 
– hemoglobin (Hb). 
Lipid peroxidation (MDA) 
Red cell lipid peroxidation was studied as thiobarbituric acid (TBA) reaction products. 
The method of Stocks and Dormandy was followed with certain modifications.10 The sample 
under test was heated with TBA at a low pH and the resulting pink chromogen, allegedly a 
(TBA)2–MDA adduct, was measured spectrophotometrically at a wavelength of 535 nm.11 An 
erythrocyte suspension (1.0 ml) was added to 8.5 ml of 0.90 % w/v normal saline and mixed 
well. Then 0.50 ml of 0.44 M H2O2 was added. 
From this mixture, a 2.5 ml of aliquot was immediately taken, to which 1.0 ml of 28 % 
trichloroacetic acid (TCA) in 0.10 M sodium metaarsenite was added. This was mixed well 
and allowed to stand for 10 min, after which it was centrifuged. An aliquot (3.0 ml) of the su-
pernatant was then taken, to which 1.0 ml of 1.0 % TBA in 50 mM NaOH was added. This 
was then kept in a boiling water bath for 15 min and then immediately cooled under tap water. 
The pink chromogen was determined spectrophotometrically at a wavelength of 535 nm. The 
values are expressed as nanomoles of MDA formed per dl of RBC, taking the molar extinction 
coefficient of the chromogen as 1.56×105 l/mol/cm.10 
MDA (10
-9 mol/100 ml of RBC) was determined using the equation: 
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=  
where AT is the absorbance of the test sample, DF is the dilution factor, V is the volume of the 
RBC suspension and ε is the extinction coefficient. 
Oxidative hemolysis of RBCs or percentage hemolysis of RBCs 
Oxidative hemolysis of the erythrocytes was measured by the method of Kartha and 
Krishnamurthy12 at 0 and 2 h, i.e., before and after 2 h incubation with H2O2. The principle of 
this method is based on the fact that an accelerated form of non-enzymatic breakdown can be 
induced in red blood cells by exposure to H2O2.10 
RBC suspension (1.0 ml) was added to 8.5 ml of 0.90 % w/v of normal saline and mixed 
well. Then 0.50 ml of 0.44 M H2O2 was added and the mixture incubated at 37 °C. 
Immediately, 0.50 ml aliquots each were withdrawn and put into 2 different centrifuge 
tubes labeled as “saline” and “water”. 
To the centrifuge tube labeled “saline”, 4.5 ml of 0.90 % w/v of normal saline was added 
and centrifuged. The supernatant was then separated and its absorbance (optical density) was 
determined at 520 nm in a colorimeter. This represented non-hemolysed RBCs (NH) at 0 h or 
before incubation with H2O2. 
To the centrifuge tube labeled “water”, 4.5 ml of distilled H2O was added and centri-
fuged. The supernatant was then separated and its optical density was determined at 520 nm in 
a colorimeter. This represented complete hemolysis of RBCs (CH) at 0 h or before incubation 
with H2O2. 
The above procedure was again repeated after 2 h incubation with H2O2 at 37 °C. The 
centrifuge tubes labeled “saline” and “water” now represented non-hemolysed (NH) and 
completely hemolysed (CH) RBCs, respectively, at 2 h or after incubation with H2O2. 
The percentage hemolysis of RBCs at 0 and 2 h was determined using the equation: 
   
(water)   CH   of   .
(saline)   NH   of   .
100     (%)   Hemolysis
O.D
O.D
=  
Vitamin E (α-tocopherol) 
Plasma vitamin E was measured using the Emmorie Engel reaction, which is based on 
the reduction of ferric to ferrous ions by tocopherols, which then form a red complex with 
α,α’-dipyridyl. Tocopherol and carotenes were extracted into petroleum ether and the ex-
tinction at 450 nm was measured. A correction was made for carotenoids after adding FeCl3. 
The reading was taken at 520 nm after 90 s.13,14 
Plasma (1.0 ml) was thoroughly mixed with 1.0 ml of redistilled 95 % ethanol in a 15 ml 
stoppered tube. Petroleum ether (3.0 ml) was then added and the tube shaken vigorously for 3 
min. This was then centrifuged and 2.0 ml of the clear supernatant was transferred to a clear 
dry cuvette. The optical density was measured at 450 nm in a colorimeter for carotenes; petro-
leum ether served as the blank. 
The petroleum ether was then evaporated off at room temperature and the residue 
dissolved in 1.0 ml of chloroform; 1.0 ml of 95 % ethanol was then added followed by 1.0 ml 
of 0.20 % α,α’-dipyridyl and 0.10 ml of 0.10 % FeCl3. After 1.5 min, the absorbance at 520 
nm was measured in a colorimeter. 
The concentration of vitamin E, mg/l of plasma, was determined using the equation: 
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where AT, AC and AS are absorbance of test, carotene and standard sample, respectively. 
Superoxide dismutase (SOD) 
The method of Beauchamp and Fridovich was followed for the measurement of SOD. 
The enzyme superoxide dismutase catalyses the reaction: 
  2 2 2
SOD
2 O O H 2H 2O + ⎯ ⎯→ ⎯ +
+ − •  
Inhibition of the reduction of nitroblue tetrazolium (NBT) by superoxide radicals, 
generated by the illumination of riboflavin in the presence of oxygen was the principle of 
SOD determination. An electron donor, methionine, was used for the assay of superoxide 
dismutase.15 
The hemolysate was prepared by the method of McCord and Fridovich.16 To 1.0 ml of 
erythrocytes (washed with 0.90 % w/v normal saline), 1.0 ml of deionized water was added to 
lyse the cells. To this, 0.50 ml of distilled ethanol followed by 0.30 ml of chloroform were 
added, mixed well and allowed to stand for 15 min. Then 0.20 ml of H2O was added and then 
the mixture was centrifuged at 4 °C. 
The supernatant contained the SOD activity and was used for the assay of SOD after 
dilution with potassium phosphate buffer (pH 7.8, 0.050 M); 0.10 ml of hemolysate was 
diluted with 1.9 ml of potassium phosphate buffer. This was the final diluted hemolysate that 
was used in the procedure given below. 
Four test tubes were taken and labeled as “test”, “control”, “test blank” and “control 
blank”. 
To the “test”, 2.9 ml of reaction mixture with NBT containing 149 mg of methionine, 
4.93 ml of NBT (1 mg/ml), 0.63 ml of riboflavin (1 mg/ml) was diluted to 100 ml with po-
tassium phosphate buffer (pH 7.8, 0.050 M) and 0.10 ml of diluted hemolysate was added. To 
the “test blank”, 2.9 ml of same reaction mixture without NBT and 0.10 ml of diluted hemo-
lysate was added. To the “Control”, 2.9 ml of same reaction mixture with NBT and 0.10 ml of 
potassium phosphate buffer (pH 7.8, 0.050 M) was added. To the “control blank”, 2.9 ml of 
the same reaction mixture without NBT and 0.10 ml of potassium phosphate buffer (pH 7.8, 
0.050 M) was added. Each of the above solutions was poured into a 10 ml beaker. The beakers 
were kept in an aluminum foil lined box fitted with a 15 W fluorescent lamp for 10 min. 
The absorbance of the solutions after irradiation was measured at wavelength of 560 nm 
in a spectrophotometer. 
One unit of SOD activity was taken as that producing a 50 % inhibition of NBT (nit-
roblue tetrazolium) reduction. The obtained values, expressed as units /g Hb, were calculated 
using the equation: 
  Unit/dl SOD (x) 
C
T C −
× =
5 10 4 . 2  
  SOD activity (units/g Hb) 
Hb
x
= (Units/g Hb of SOD) 
where C and T are the absorbance of the control and test, respectively. 
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Estimation of hemoglobin 
The hemoglobin content of the erythrocytes was determined by the cyanmethemoglobin 
method.17 
Hemoglobin was treated with a reagent containing potassium ferricyanide, potassium 
cyanide and potassium dihydrogen phosphate (Drabkins Reagent). The ferricyanide oxidizes 
hemoglobin to methemoglobin, which is converted to cyanmethemoglobin by the cyanide. 
The absorbance was measured at 540 nm in a colorimeter. 
RBC suspension (20 μl) was added to 4.0 ml of ferricyanide reagent and allowed to stand 
for 4 min. The absorbance was measured at 540 nm in a colorimeter against a reagent blank. 
The absorbance of the standard solution was measured by directly taking 4.0 ml of a standard 
cyanmethaemoglobin solution (60 mg/dl).18 
Hemoglobin (g/dl) was determined using the equation: 
 
S
T
1000
  (mg/dl)   std.   of   Conc.   factor  Dilution   
    (g/dl)   Hemoglobin
A
A × ×
=  
where Conc. of std. is 60 mg/dl. 
Statistical analysis 
All the biochemical parameters were compared using the Fishers F-test for analysis of 
variance (ANOVA), except for hemolysis. The student’s paired t-test was used for hemolysis 
(0 and 2 h). The statistical software SPSS (statistical package for social sciences), version 11, 
was used for this purpose. 
RESULTS AND DISCUSSION 
In this study, the products of lipid peroxidation, hemolysis of RBCs and anti-
oxidant levels were compared between those having a high cholesterol level, those 
who had been on treatment with atorvastatin for a minimum of 2 months (mini-
mum dosage of 10 mg/day) and those individuals of the same age group having a 
normal lipid profile, who were taken as controls. 
Free oxygen radicals and insufficient antioxidant enzymes have been impli-
cated in the pathogenesis of hypercholesterolemia.2,4,19,20 Statins have been used 
effectively for the treatment of hypercholesterolemia.2,20,21 These facts formed 
the basis of this study, i.e., to investigate the antioxidant system and oxidative 
stress in hypercholesterolemic patients, as well as in patients who had been treat-
ed with atorvastatin for a minimum of 2 months. 
The mean total cholesterol levels of the 3 groups are given in Table I. In pa-
tients taking atorvastatin, the mean total cholesterol was reduced after 2 months 
of treatment (246.66±8.54 mg/dl) as compared to the hypercholesterolemic pa-
tients (325.33±11.23 mg/dl). 
RBC malondialdehyde (MDA) 
As a measure of oxidative stress, MDA, the end-product of lipid peroxida-
tion, was estimated by the TBA method. RBC MDA levels were highest in the 
hypercholesterolemic group (742.67±74.10 μmol/l) and lowest in control group 
(545.63±48.03 μmol/l). These values are statistically highly significant (p = 0.001) 
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when the hypercholesterolemic group was compared with the control group and 
statistically significant (p = 0.034) when the atorvastatin group was compared 
with the control group, as indicated in Table II. 
TABLE I. Mean total cholesterol levels of the 3 groups, i.e., control, atorvastatin and hyper-
cholesterolemic 
Group  No. of subjects Mean total cholesterol level, mg/dl
a 
Control 15  161.25±5.43 
After a minimum of 2-months- 
-atorvastatin therapy 
15 246.66±8.54 
Hypercholesterolemic   15  325.33±11.23 
aMean±SD 
TABLE II. Mean RBC MDA levels of the 3 groups (control, atorvastatin and hypercholes-
terolemic) determined by Fisher’s F-test 
Group  No. of subjects Mean, μmol/l  SD p  Remarks  
Control 
Atorvastatin 
Hypercholesterolemic 
15 
15 
15 
545.63 
590.23 
742.67 
48.03 
39.63 
74.10 
– 
0.034 
0.001 
– 
S
a 
HS
b 
aSignificant; 
bhighly significant 
The high level of MDA in the hypercholesterolemic group suggests an in-
crease in oxidative stress in patients with hypercholesterolemia. Its relatively lower 
level in the atorvastatin group suggests a decrease in oxidative stress. These find-
ings further confirm the antioxidant properties of statins such as atorvastatin.2 
Percentage hemolysis of RBCs and vitamin E 
The percentage hemolysis of RBCs was measured as an indicator of damage 
to RBC membranes as a result of oxidative stress. Amongst the antioxidants, vi-
tamin E was chosen because, despite its low molar concentration in membranes, 
it effectively serves as the major lipid-soluble, chain-breaking antioxidant.22 This 
study showed an increased hemolysis of RBCs in the hypercholesterolemic group 
(4.52±1.06 %) as compared to the atorvastatin (2.48±0.67 %) and control groups 
(1.69±1.04 %), but in the atorvastatin group it was more than in the control but 
less than the hypercholesterolemic group, both before (2.48±0.67 %) and after in-
cubation (3.52±0.81 %) with hydrogen peroxide (Table III). The values are statis-
tically highly significant both before and after incubation with hydrogen peroxide 
(p < 0.05). This could be explained based on increased oxidative stress in the hy-
percholesterolemia patients
 and the effect of atorvastatin in reducing oxidative 
stress in the hypercholesterolemic patients after 2 months of treatment. The mean 
vitamin E levels were lower in the atorvastatin group (7.74±1.05 mg/dl) and the 
lowest in hypercholesterolemic group (6.28±0.68 mg/dl) as compared to the con-
trol group (9.31±1.36 mg/dl) as shown in Table IV. The values are statistically 
highly significant (p < 0.05). Studies showed that vitamin E plays a critical role 
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in protecting the polyunsaturated fatty acids of cell membranes against lipid pe-
roxidation through its free-radical quenching activity at an early stage of free-ra-
dical attack, thus suppressing hemolysis.22 This has made vitamin E one of the 
important factors determining the susceptibility of red cells to auto-oxidation he-
molysis.22 Vitamin E appeared to be highly efficient as an antioxidant and is ac-
cepted as the first line of defense against lipid peroxidation.22–25 
TABLE III. Percentage hemolysis of RBCs before and after incubation with H2O2 in the 3 
groups (control, atorvastatin and hypercholesterolemic). Name of the test used: Fisher’s F-test 
Group  No. of subjects  Mean  SD p  Remarks   
Hemolysis before incubation  
Control 
Atorvastatin  
Hypercholesterolemic  
15 
15 
15 
1.69 
2.48 
4.52 
1.04 
0.67 
1.06 
– 
0.001 
0.001 
– 
HS
a 
HS 
Hemolysis after incubation 
Control  
Atorvastatin  
Hypercholesterolemic 
15 
15 
15 
2.78 
3.52 
6.01 
0.88 
0.81 
1.12 
– 
0.001 
0.001 
– 
HS 
HS 
aHighly significant 
The popular finding that vitamin E is inversely related to the respective tis-
sue MDA level fits here as the MDA level in this study was found to be the high-
est in the hypercholesterolemic group (742.67±74.10 μmol/l) and the lowest in 
control group (545.63±48.03 μmol/l). The increased hemolysis of RBCs in the 
hypercholesterolemic group could be further documented by the decreased levels 
of vitamin E, which is the first line of defense against membrane damaging lipid 
peroxidation.22–25 
In the atorvastatin group, the level of vitamin E was more than in the hyper-
cholesterolemic group but less than in the control group (Table IV). The results 
of percentage hemolysis of RBCs were in the same order; hemolysis was the 
lowest in the control group, higher in the atorvastatin group and the highest in the 
hypercholesterolemic group. The controls had the highest level of vitamin E as 
they are considered to be the group with the least oxidative stress due to the nor-
mal lipid profile of their blood. It may be hypothesized that due to increased oxi-
dative stress in the hypercholesterolemic group, the utilization of vitamin E, which 
is an antioxidant, might have increased. This agrees with the work of Moriel et al.19 
TABLE IV. Plasma vitamin E levels of the 3 groups (control, atorvastatin and hyperchole-
sterolemic). Name of the test used: Fisher’s F-test 
Group  No. of subjects  Mean, mg/dl  SD p  Remarks   
Control 
Atorvastatin  
Hypercholesterolemic 
15 
15 
15 
9.31 
7.74 
6.28 
1.36 
1.05 
0.68 
– 
0.001 
0.001 
– 
HS
a 
HS 
aHighly significant 
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Superoxide dismutase (SOD) 
Superoxide dismutase was chosen in this study as it plays an important role 
in the removal of superoxide radicals ( − •
2 O ) formed in red cells and because he-
moglobin and SOD were shown to be in close association with red cells. In addi-
tion to this, some studies also suggested that SOD is one of the most important 
enzymes in the front line of defense against oxidative stress
 and is the most ef-
fective in protecting RBCs against damage by exogenous superoxide radicals 
( − •
2 O ), especially at higher concentrations.26–28 This study showed low levels of 
SOD in the hypercholesterolemic group (6.28±0.69 units/mg), as shown in Table 
V. In the atorvastatin group, the SOD level (7.74±1.05 units/mg) was more than 
in the hypercholesterolemic but less than in the controls. The values were statisti-
cally highly significant (p < 0.05). Low levels of SOD in the cellular and extra-
cellular fluids reduce their oxygen-derived, free radical (ODFR) scavenging ca-
pacity, making the tissues more vulnerable to ODFR damage.28 The low level of 
SOD found in hypercholesterolemic patients is indicative of increased oxidative 
stress in patients with hypercholesterolemia (Table V). Studies that showed that 
there is a reduced activity of SOD in hypercholesterolemia, which improved after 
3 months of treatment with fluvastatin, further strengthens the idea of increased 
oxidative stress in hypercholesterolemics and reduction of oxidative stress after 
the use of atorvastatin, which inhibits superoxide anion production, preserves in-
tracellular SOD and prevents ROS (reactive oxygen species) permeation into li-
poproteins.2,26,27 Thus, it can be concluded that the trends seen in this study defi-
nitely suggest that there is an increased occurrence of oxidative stress as a result 
of hypercholesterolemia and that after the use of atorvastatin, the oxidative stress 
decreased, for which there may be two reasons. The first reason may be due to 
the decreased cholesterol levels and the second, due to the anti-oxidant effect of 
atorvastatin, as shown in many studies. 
TABLE V. RBC superoxide dismutase (SOD) levels in the 3 groups (control, atorvastatin and 
hypercholesterolemic). Name of the test used: Fisher’s F-test 
Group  No. of subjects  Mean, units/mg SD p  Remarks   
Control 
Atorvastatin 
Hypercholesterolemic 
15 
15 
15 
8078.63 
7432.69 
5281.79 
762.50 
657.92 
525.19 
– 
0.001 
0.001 
– 
HS
a 
HS 
aHighly significant 
CONCLUSIONS 
This study was an attempt to establish the extent of increased oxidative 
stress in hypercholesterolemic patients and to evaluate the effect of atorvastatin 
on the oxidative stress and antioxidant status after 2 months of treatment. 
The levels of oxidative stress were higher in the hypercholesterolemic pa-
tients than in the control and atorvastatin groups. The levels of oxidative stress in 
2009 Copyright (CC) SCS
___________________________________________________________________________________________________________________________ Available online at www.shd.org.rs/JSCS/1072 NASAR  et al. 
the atorvastatin group were lower than in the hypercholesterolemic group but 
higher than in the control group. The levels of antioxidants were higher in the 
atorvastatin group than hypercholesterolemic group but were lower than in the 
controls. From these findings, it can be concluded that there is an increase in oxi-
dative stress in hypercholesterolemia but it decreases significantly after 2 months 
of atorvastatin therapy and there is simultaneously an improvement in the anti-
oxidant status in patients taking atorvastatin. 
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лестеролемијом и праћен је ефекат аторвастатина на оксидативни стрес и антиоксидативни 
статус. Анализирана је плазма људи из три групе (по 15 узорака): здрави људи, пацијенти са 
хиперхолестеролемијом на терапији аторвастатином и пацијенти са хиперхолестеролемијом 
без терапије. У плазми је одређиван витамин Е. Изоловане ћелије су испране три пута хлад-
ним физиолошким раствором и коришћене су за одређивање степена хемолизе еритроцита и 
концентрације малондиалдехида, супероксид-дисмутазе и хемоглобина. Степен оксидатив-
ног стреса је био већи код пацијената без терапије него код здравих особа и пацијената на 
третману аторвастатином. Ниво антиоксиданаса је био већи код пацијената под терапијом, 
али ипак мањи него у контролној групи. На основу резултата је закључено да је оксидативни 
стрес повећан код пацијената са хиперхолестеролемијом, али да се значајно смањује после 
двомесечне терапије аторвастатином, уз побољшање антиоксидативног статуса. 
(Примљено 26. фебруара, ревидирано 7. маја 2009) 
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